Elevance Health (ELV) has seen its net margin thin to 2.5% from a three-year average of 3.2%, primarily due to underperformance in its Medicaid segment. While the company has successfully restructured its Medicare Advantage business, it is now focusing on repairing Medicaid margins, including exiting unprofitable markets. Management's 2026 adjusted earnings-per-share guidance relies on Medicare Advantage and individual ACA, and the second half of 2026 will be crucial in determining if the Medicaid margin outlook is a prudent reflection or a sign of deeper issues.

Amgen's stock (AMGN) fell sharply by 10% after Novartis' cholesterol drug Pelacarsen failed a Phase 3 trial, even though Amgen was not directly involved. Analysts believe the sell-off was overdone as Amgen's own cholesterol candidate, Olpasiran, differs significantly in potency and dosing, and its established PCSK9 drug, Repatha, continues to show strong revenue growth. Despite the market reaction, institutional investors are reportedly focusing on Amgen's strong balance sheet rather than the competitor's trial results.

A class action lawsuit has been filed against Lowe's Cos. Inc. alleging that the retailer raised prices to cover tariffs imposed by the International Emergency Economic Powers Act, then failed to reimburse shoppers after receiving $80 million in government refunds. The lawsuit claims Lowe's is unjustly enriching itself by keeping these refunds without establishing a process to repay customers who bore the initial costs through higher prices. The suit seeks to represent a nationwide class of shoppers and demands that Lowe's repay the tariff costs or distribute a proportionate share of the refunds.

Digital Realty Trust (DLR) stock is trading higher after BTIG raised its price forecast, citing accelerating demand for AI infrastructure and a growing development pipeline. BTIG noted stronger data center demand driven by hyperscaler spending and cloud growth, maintaining a Buy rating and increasing the price target to $220. The firm views DLR's recent pullback as a buying opportunity, emphasizing the strengthening fundamental backdrop for data centers.

Colgate-Palmolive (CL) stock dipped 1% after reports surfaced that the company plans to sell some of its personal care brands, including Softsoap, Irish Spring, and Speed Stick, to raise approximately $1 billion. Despite strong recent financial results, including beating EPS estimates and matching revenue expectations, CL stock has underperformed the broader market over the last five years. Wall Street analysts currently give Colgate-Palmolive a Moderate Buy rating with an average price target implying 14% upside.

Daré Bioscience is transitioning from a development-stage biotech to a commercial-stage women's health company, with two revenue-generating products launching or recently launched and a pipeline of additional products. The company emphasized its integrated commercial model through DARE Health Hub, telehealth, and digital marketing, highlighting that women's health is an underserved market with significant commercial opportunity. Daré also noted its strong cash position and success in securing over $75 million in non-dilutive funding since 2017 to advance its pipeline, including Ovaprene and DARE-HPV.

Clipper Realty (NYSE:CLPR) Director Sam Levinson purchased 6,842 shares of the company's stock for $22,168.08, increasing his total holdings to 268,304 shares. This transaction is part of a series of recent purchases by Levinson, highlighting continued insider buying. The article also notes the company's dividend yield of 11.3% and its recent downgrade by Wall Street Zen from "hold" to "sell."

Carpenter Technology (CRS) is experiencing significant growth driven by strong demand in its aerospace and defense markets, with sales up 15% in fiscal 2026. The company is also seeing an uptick in Industrial, Consumer, and Transportation sectors, offsetting a slight dip in Medical. With robust booking growth and favorable market trends, Carpenter Technology projects strong operating income growth for fiscal years 2027 and 2029.

California Water Service Group's (CWT) unit, Washington Water, received approval for new water rates, expected to increase annual revenues by $4.1 million to recover costs from infrastructure investments totaling $26.5 million. This approval highlights CWT's ongoing focus on infrastructure spending and regulatory cost recovery, with the company investing significantly in utility plant and forecasting substantial capital expenditures for 2026. Rate hikes are crucial for utilities to fund capital-intensive operations, maintain and upgrade aging systems, and support reliable service and water quality improvements.

Denison Mine (NYSEAMERICAN:DNN) shares dropped 4.5% on Friday, trading at $3.0850 with significantly lower than average trading volume. Despite the dip, analysts maintain a "Moderate Buy" consensus with an average price target of $5.38, and institutional investors like VanEck and Vanguard have recently increased their stakes. Denison Mines is a Canada-based uranium exploration and development company focused on high-grade uranium projects in the Athabasca Basin, with its flagship asset being the Wheeler River Project.